

## RESEARCH ARTICLE

# On PTV definition for glioblastoma based on fiber tracking of diffusion tensor imaging data

Barbara Witulla<sup>1</sup>, Nicole Goerig<sup>1</sup>, Florian Putz<sup>1</sup>, Benjamin Frey<sup>1</sup>, Tobias Engelhorn<sup>2</sup>, Arnd Dörfler<sup>2</sup>, Michael Uder<sup>3</sup>, Rainer Fietkau<sup>1</sup>, Christoph Bert<sup>1\*</sup>, Frederik Bernd Laun<sup>3</sup>

**1** Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, **2** Department of Neuroradiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, **3** Institute of Radiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

\* [christoph.bert@uk-erlangen.de](mailto:christoph.bert@uk-erlangen.de)



## OPEN ACCESS

**Citation:** Witulla B, Goerig N, Putz F, Frey B, Engelhorn T, Dörfler A, et al. (2020) On PTV definition for glioblastoma based on fiber tracking of diffusion tensor imaging data. PLoS ONE 15(1): e0227146. <https://doi.org/10.1371/journal.pone.0227146>

**Editor:** Jonathan H Sherman, George Washington University, UNITED STATES

**Received:** August 16, 2019

**Accepted:** December 11, 2019

**Published:** January 6, 2020

**Copyright:** © 2020 Witulla et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Our ethics approval allows us to evaluate the data after pseudonymization. A complete pseudonymization of brain data is apparently difficult because the possibility of rendering the surface of the high resolution head image data potentially allows an identification of the patients despite anonymizing the data. The restrictions are imposed by law, especially the EU General Data Protection Regulation (GDPR), the German Data Protection Laws and the Bavarian Hospital law. Thus the data is available upon request. Data requests can be

## Abstract

Radiotherapy (RT) is commonly applied for the treatment of glioblastoma multiforme (GBM). Following the planning target volume (PTV) definition procedure standardized in guidelines, a 20% risk of missing non-local recurrences is present. Purpose of this study was to evaluate whether diffusion tensor imaging (DTI)-based fiber tracking may be beneficial for PTV definition taking into account the prediction of distant recurrences. 56 GBM patients were examined with magnetic resonance imaging (MRI) including DTI performed before RT after resection of the primary tumor. Follow-up MRIs were acquired in three month intervals. For the seven patients with a distant recurrence, fiber tracking was performed with three algorithms and it was evaluated whether connections existed from the primary tumor region to the distant recurrence. It depended strongly on the used tracking algorithm and the used tracking parameters whether a connection was observed. Most of the connections were weak and thus not usable for PTV definition. Only in one of the seven patients with a recurring tumor, a clear connection was present. It seems unlikely that DTI-based fiber tracking can be beneficial for predicting distant recurrences in the planning of PTVs for glioblastoma multiforme.

## Introduction

A good outcome in radiation therapy requires a good definition of the planning target volume by means of imaging techniques like computer tomography (CT) or magnetic resonance imaging (MRI). For brain tumors, the use of MRI is advisable because of the good soft tissue contrast [1]. In case of glioblastoma (GBM, annual incidence of approximately 5000 cases in Germany, which has a population of roughly 83 million people [2]), MRI images are acquired before and after surgical removal of the visible tumor area for defining the clinical target volume (CTV). The “American Society of Clinical Oncology” recommends resection with consequent external beam radiation therapy (RT) [3, 4]. The target volume should include the area of the tumor before resection and the cavity after resection. Moreover, anatomical limits like edema, bones etc. should be taken into account when defining the target volume [3, 4]. The

send to Prof. Dr. Rainer Fietkau (Chair Radiation Oncology, [rainer.fietkau@uk-erlangen.de](mailto:rainer.fietkau@uk-erlangen.de)), Jan Köster (Data Security Officer, [datenschutz@uk-erlangen.de](mailto:datenschutz@uk-erlangen.de)) or Prof. Dr. Christoph Bert ([christoph.bert@uk-erlangen.de](mailto:christoph.bert@uk-erlangen.de)) stating the patient ID.

**Funding:** The authors received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

five year survival rate is between 25% and less than one percent depending on age and therapy [5, 6]. This stresses the need for better therapeutic approaches including, for example, a better target volume definition [7].

In about 20% of the glioblastoma patients, their recurrence was diagnosed as distant [8] and invasive glioma cells are found to migrate along myelinated fiber tracts of white matter [9]. The orientation of these tracts can be revealed with magnetic resonance diffusion tensor imaging (DTI) [10]. In DTI, the average water diffusion properties in an image voxel are detected and the larger diffusion parallel to white matter fiber tracts indicates their direction. Based on these data, white matter tracts can be reconstructed with fiber tracking techniques [11]. In a pioneering work, Krishnan et al. found that DTI-based fiber tracts connected primary glioma tumors with secondary lesions in eleven out of fourteen patients. They stated that this approach may be used to modify stereotactic radiotherapy target volumes to provide elongated treatment margins along the paths of elevated water diffusion, thereby creating a biologically better treatment plan that may reduce the incidence of progression [12].

Following this idea, we hypothesized that fiber tracking might be helpful for the definition of PTVs for radiation therapy of GBMs, and that the advances in scanner hardware and fiber tracking algorithms might lead to improved results. The aim of this work was to test this hypothesis.

## Material and method

### Patients

One hundred fifty-two patients were treated for brain tumors at the Department of Radiation Oncology at the University Hospital Erlangen from January 2015 until March 2017. Fifty-six patients were diagnosed with GBM, 30 of which developed a recurrence. Seven out of these 30 patients had a distant recurrence. These seven patients were included in this retrospective study.

The department of Neuroradiology and the institute of Radiology, which were involved in the patients' treatment, agreed on using routine clinical data. All patients provided written informed consent when enrolled to the IRB approved study (No. 265\_14B, Clinicaltrial ID: NCT02600065, ethics committee of the Friedrich-Alexander University Erlangen-Nürnberg).

### CT imaging

The planning CT for initial tumors as well as for recurrences was acquired at Sensation Open (Siemens Healthineers, Erlangen, Germany) with acquisition matrix  $512 \times 512$ . The voxel size depended on the reconstruction type. The slice thickness varied between 1 mm and 3mm and the pixel spacing varied between  $0.7 \times 0.7 \text{ mm}^2$  and  $0.98 \times 0.98 \text{ mm}^2$ .

### MRI

The MRI scanning protocol included T1-weighted imaging (field of view (FoV)  $192 \text{ mm} \times 320 \text{ mm}$ , acquisition matrix  $320 \times 320$ , voxel size  $0.72 \times 0.72 \times 5 \text{ mm}^3$ , repetition time (TR) 407 ms, and echo time (TE) 8.8 ms, 25 slices and 1 mm slice gap), T2 fluid attenuation inversion recovery imaging (FoV  $230 \text{ mm}^2$ , matrix  $512 \times 512$ , voxel size  $0.45 \times 0.45 \times 5 \text{ mm}^3$ , TR 9000 ms, TE 110 ms, and inversion recovery time 2500 ms, 25 slices and 1 slice mm gap), and a T2-MP-Rage sequence (FoV  $256 \times 256 \text{ mm}^2$ , matrix  $256 \times 256$ , voxel size  $0.98 \times 0.98 \times 1 \text{ mm}^3$ , TR 1900 ms, TE 3.02 ms, inversion recovery time 1100 ms, 176 slices and 0.2 mm gap). The parameters of the echo planar DTI sequence were:  $b = 0$  and  $1000 \text{ s/mm}^2$ , 20 diffusion directions, FoV  $256 \times 256 \text{ mm}^2$ , matrix  $128 \times 128$ , voxel size  $2 \times 2 \times 2 \text{ mm}^3$ , TR 10,500 ms, TE 93

ms, and an acquisition bandwidth of 1628 Hz/pixel. Data were acquired at a 1.5 Tesla MAGNETOM Aera (Siemens Healthineers, Erlangen, Germany) with a 20 channel head coil. MRI exams were conducted according to the standard clinical protocol: post resection, before RT and in three month intervals after the end of RT. For one patient, the first DTI was acquired after resection and during RT.

### Image registration

The radiation therapy treatment was planned with the treatment planning system (TPS) Pinnacle<sup>3</sup> (Philips Healthcare, Eindhoven, The Netherlands), with the target volume (gross tumor volume according to ICRU Reports 50 and 62) definition performed in iPlan RT Image 4.1.2 (Brainlab, Munich, Germany) and based on rigidly registered CT and MRI acquired before RT ( $CT_{\text{plan}}$  and  $MRI_{\text{plan}}$ ) by experienced oncologists in the routine workflow. The initial gross tumor volume (GTV), PTV, edema, and organ at risk (OAR) ( $ROI_{\text{plan}}$ ) structures, as well as the  $CT_{\text{plan}}$ , were exported to the research platform.

Before starting fiber tracking, the DTI data after surgical removal of the tumor ( $DTI_{\text{plan}}$ ) and the MP-rage of the recurrence ( $MRI_{\text{recurrence}}$ ) were registered rigidly on  $CT_{\text{plan}}$  by a radiation oncologist in iPlan RT Image 4.1.2 (Brainlab, Munich, Germany). The recurrence was also defined by a physician on  $CT_{\text{plan}}$  based on  $MRI_{\text{recurrence}}$ . The recurrence structure ( $ROI_{\text{recurrence}}$ ) was exported. Then,  $CT_{\text{plan}}$  was rigidly registered to  $DTI_{\text{plan}}$  using the open source software Plastimatch ([www.plastimatch.org](http://www.plastimatch.org)) to get the transformation matrix ( $M_t$ ).  $M_t$  was applied on the  $ROI_{\text{plan}}$ . As  $ROI_{\text{recurrence}}$  was defined on  $CT_{\text{plan}}$  for initial tumor treatment, it was also propagated to  $DTI_{\text{plan}}$  by  $M_t$ .

### DTI processing, DTI analysis and fiber tracking

**iPlan.** Streamline tractography was conducted using the fiber tracking module of iPlan Image 4.1.2 (Brainlab AG, Munich, Germany). The DTI images were imported into iPlan and corrected for eddy currents [13]. iPlan uses the tensor deflection (TEND) fiber tracking algorithm with fractional anisotropy (FA) and value of minimum fiber length as stopping criteria [13]. We set the criteria to  $FA = 0.3$  (recommendation made in a personal communication by Brainlab staff) and a minimum length of 50 mm. Three different seed regions were used: (i) GTV enlarged by 2 mm (seed  $GTV_{+2\text{mm}}$ ), (ii) GTV enlarged by 4 mm (seed  $GTV_{+4\text{mm}}$ ), (iii) recurrence volume (seed b). If more than one recurrence volume was present, the recurrence volumes were investigated separately. It was evaluated whether a connection between extended GTV volume and recurrence volume existed. If one or more of the tracked fibers entered both volumes, a connection was assumed to be present. Additionally, the strength of the connection was rated subjectively to be weak, middle, or strong.

**MITK.** Treatment planning CT ( $CT_{\text{plan}}$ ), initial GTV, recurrence structure ( $ROI_{\text{recurrence}}$ ) and the DTI ( $DTI_{\text{plan}}$ ) were co-registered and imported into the open source toolkit MITK-Diffusion ([www.mitk.org](http://www.mitk.org)). A discrete Gaussian noise filter with variance of 2 arbitrary units (a.u) was applied to the DTI raw data. Afterwards, a tensor map was generated via the module "Tensor" with a threshold of 50 a.u. on the  $b_0$  image to eliminate regions outside of the brain.

MITK Diffusion provides the opportunity of Gibbs tracking [14] and streamline tracking [11, 15–19]. The fibers were generated by streamline tracking with a FA threshold of 0.3 and the fiber assignment by continuous tracking (FACT) algorithm (MITK parameters  $f = 1$  and  $g = 0$ , see also [17]) with minimal tract length of 50 mm. The same seed volumes as in iPlan were used.

In contrast to streamline tracking, Gibbs tracking is a global method for generating all fibers in the brain. Fibers are found by minimizing a cost function that guarantees consistency with

the measured data and smoothness of fibers. This approach allows fibers to traverse fiber crossing regions. In contrast, using streamline techniques often results in premature fiber terminations in crossing regions because these regions are associated with small FA values in DTI. Gibbs tracking is able to overcome this limitation and can thus potentially unveil connections that are not found with streamline tracking.

Gibbs tracking in MITK features several parameters which can be set individually. The parameter particle length, particle width, particle weight and random seed were set to “auto”. Start Temperature was 0.1 a.u. and End Temperature was 0.001 a.u. The parameter balance of In/Ex Energy was set to 0. The parameter curvature threshold was  $45^\circ$  and the minimum fiber length was 50 mm.  $10^8$  iterations were calculated.

After generating fibers by streamline and Gibbs tracking, they were extracted with help of the MITK “Fiber extraction” tool to find the fibers that pass the volumes of interest. I.e., the fibers generated by streamline tracking with seed GTV + enlargement were extracted for passing the recurrence volume. The fibers generated by seed b were extracted for passing GTV<sub>+2mm</sub> or GTV<sub>+4mm</sub>. For Gibbs tracking, those fibers were extracted that passed GTV + enlargement and recurrence volume. The strength of the connection was rated subjectively in consensus by BW and FBL to be weak, middle, or strong. The rating “weak” was given if only a few connecting fibers were present, which subjectively could easily be attributed to origin from tracking errors. The rating “strong” was given if a doubtless connection was present. The rating “middle” was given otherwise.

## Results

[Fig 1](#) shows the fiber tracking results obtained with iPlan with seed GTV<sub>+4mm</sub>. For patient 6, a strong connection between seed volume and recurrence volume 1 (displayed in cyan color) is visible. However, in all other cases, either only a weak connection is present, where the fibers are only touching the rim of the recurrence region (e.g. for patient 3) or no connection is present (e.g. for patient 2).


[Fig 2](#) shows the fiber tracking results obtained with iPlan with different seed volumes for patient 6. Concerning the volume of the second recurrence displayed in purple, no connection is visible for seed GTV<sub>+4mm</sub> ([Fig 2a](#)). However, a connection is present for seed b (purple volume, [Fig 2b](#)); i.e. it matters whether the tractography is started in the GTV or in the recurrence volume.

[Fig 3](#) is structured similar as [Fig 1](#), but shows the tracking results of the MITK streamline tractography. Generally, less fibers were tracked than in iPlan although similar termination criteria were used. Consequently, even the strong connection observed for patient 6 in [Fig 1](#) reduces to a weak connection. The different volume sizes in [Figs 1](#) and [3](#) arise from the registration onto the DTI dataset.

[Fig 4](#) shows the result of the Gibbs tracking, showing all fibers that enter or pass the GTV<sub>+4mm</sub>. In comparison to the other two tracking approaches, much more fibers are generated often penetrating most of the brain volume. Consequently most recurrences feature some connection to the GTV<sub>+4mm</sub>.

[Fig 5](#) also shows Gibbs tracking results. Unlike in [Fig 4](#), only those fibers are shown that enter or pass the GTV<sub>+4mm</sub> and the recurrence volume. Thus, much less fibers are shown than in [Fig 4](#). Still, a strong connection is again visible for patient 6. However, unlike in [Figs 1](#) and [3](#), patients 1, 5, and 7 also have strong connections between GTV<sub>+4mm</sub> and recurrence volumes.

[Table 1](#) shows the quantitative and subjective evaluation of strength of the connection between GTV<sub>+2mm</sub> (upper part) and GTV<sub>+4mm</sub> (lower part), and the recurrences. For all




**Fig 1. Fibers generated by iPlan.** Fibers generated with  $GTV_{+4mm}$  as seed in iPlan. The yellow volume is the  $GTV_{+4mm}$ . The recurrence volumes are displayed in cyan, and in purple if a second recurrence volume is presented. The fiber color indicates the fiber direction (blue: cranio-caudal, red: left-right, green: anterior-posterior).

<https://doi.org/10.1371/journal.pone.0227146.g001>

recurrences, existence and strength of a detected connection strongly depended on the used algorithm and target volumes.

## Discussion

Of the 152 considered patients, seven had a distant recurrence. For one of these patients (patient 6), all used tracking approaches with seed  $GTV_{+4mm}$  found a strong connection between the GTV and one of the recurrences (recurrence 1). For the second recurrence of



**Fig 2. Fibers generated by iPlan for patient 6.** Result of streamline tracking in iPlan for patient 6 with different seeds: A) seed  $GTV_{+4mm}$  (yellow volume), B) seed recurrence 2 (purple volume) (B).


<https://doi.org/10.1371/journal.pone.0227146.g002>

patient 6 and for the six other patients, the presence and strength of the connection depended strongly on the used tracking algorithm and on the seed volume definition.

The results indicate that the usefulness of fiber tracking methods for inclusion of distant recurrences in the definition of the PTV is rather limited for GBM patients. We used three different tracking approaches and observed the well-known strong dependency of tracking results on the used algorithm [20–23]. It may be argued that the variance of obtained results may be minimized by properly harmonizing the whole pipeline from acquisition protocol, seed volume definition, tracking method and tracking criteria, to the evaluation of the results. But the problem that the position of the recurrences was not predictable with our tracking data was present for each of the tested methods. For the two streamline tracking techniques, connections were mostly not present or only very weak. The Gibbs tracking approach yielded clear connection for more patients, which were, however, only identifiable retrospectively (Fig 5). At the time point of PTV delineation, only the GTV is known (as in Fig 4). However, the Gibbs tracking based on the GTV resulted in connections to almost all brain regions, which limits its predictive value. Thus, it seems unlikely that an optimization of parameters or the use of more advanced tracking algorithms—like machine learning techniques [15]—might help in this regard.

The reason for this negative finding is presumably twofold. First, it seems that a connection via large white matter fiber bundles is not a necessity for lesion spreading (as, for example, for patient 4). Second, the lesion may occur at quite distant position with respect to the primary tumor like in patient 2. Even if all distant lesions were connected to the primary tumor, knowing the fiber structure would not help for treatment planning because the lesions could still appear basically anywhere in the brain. This makes a well-conducted radiation dose boosting extremely challenging.

The results of Krishnan et al. were more promising than ours in terms of the predictive value of fiber tracking [12]. They included several glioma types with different therapies




**Fig 3. Fibers generated by streamline algorithm in MITK.** Fibers generated with  $GTV_{+4mm}$  as seed by streamline algorithm in MITK. The yellow volume is the GTV increased by 4 mm. Recurrences are displayed in cyan and purple. Coloring of the fibers is identical to Fig 1.

<https://doi.org/10.1371/journal.pone.0227146.g003>

including only three patients post resection out of 14 patients in total, while we focused on GBMs after resection. This is, however, unlikely to explain the observed difference, since two out of three GBM patients had a strong connection in [12] for the distant secondary tumor group, which comes closest to our patient population. It seems more likely that the low number of patients in the two studies (14 in [12] and 7 in our study) and the associated large statistical uncertainty is the major reason for the observed differences.

DTI data have been used successfully in the context of glioma evaluation in several regards. For example, they have been used to adapt target volume definitions for GBM treatment



**Fig 4. Fibers generated by Gibbs tracking in MITK.** Result of Gibbs tracking for all patients after extraction. The fibers which pass  $GTV_{+4mm}$  (yellow volume) are shown. Recurrences are displayed in cyan and purple.


<https://doi.org/10.1371/journal.pone.0227146.g004>

planning [24–26], for modeling of brain tumor growth [27–30], to detect early malignant transformation of low-grade glioma [31], to differentiate between GBM and brain metastases [32], to use DTI-derived fiber tracking in surgery planning [33], and to detect the infiltration of the corpus callosum [34]. Our inability to properly connect most primary and secondary tumors does not diminish the value of DTI for these applications.

Potentially, other MRI techniques such as resting state functional MRI might represent potential venues for future research directions to relate the functional connectivity of the brain in GBM patients with the occurrence of new lesions [35].

One limitation of this study is the small patient number (seven patients with ten recurrences), which may be explained by the rareness of GBM and the low percentage of distant recurrences in GBM. Because of the surgical removal, a cavity occurred, which most likely resulted in a shift of brain anatomy [36–38]. Several physicians were involved in the definition of GTV and PTV treatment. If only one physician had planned GTV and PTV, the associated well-known inter-user variance could have been avoided [39]. One further limitation was the limited available scan time. Using 30 or more gradient directions would have stabilized the





**Fig 5. Connecting fibers generated by Gibbs algorithm.** Connecting fibers from  $GTV_{+4mm}$  (yellow volume) to recurrences (cyan and purple volumes) generated by the Gibbs algorithm.

<https://doi.org/10.1371/journal.pone.0227146.g005>

diffusion tensor calculation [40]. Advanced diffusion techniques that use higher b-values and generally require more scan time might also have improved the tractography results. These techniques include e.g. spherical deconvolution [41], neurite orientation dispersion diffusion imaging (NODDI) [42], higher order tensor reconstructions [43], or q-ball imaging [44]. The use of a higher field strength of 3 T or even 7 T would have been beneficial with respect to the signal to noise ratio and thus might have improved the tracking results [45].

**Table 1. Observed connection between extended GTV and recurrence volume.**

patient identification	iPlan		streamline algorithm in MITK		Gibbs algorithm in MITK
	seed		seed		
	GTV <sub>+2mm</sub>	recurrence	GTV <sub>+2mm</sub>	recurrence	
1 (recurrence 1)	no	no	no	no	yes (weak, 7)
1 (recurrence 2)	no	no	no	no	yes (strong, 23)
2	no	no	no	no	yes (weak, 3)
3	no	yes (weak)	no	no	no
4	no	no	no	no	yes (weak, 1)
5	no	yes (strong)	no	no	yes (strong, 19)
6 (recurrence 1)	yes (strong)	yes (strong)	no	no	yes (strong, 55)
6 (recurrence 2)	no	no	no	no	yes (weak, 5)
7 (recurrence 1)	no	no	no	no	yes (middle, 10)
7 (recurrence 2)	no	no	no	no	yes (strong, 43)

patient identification	iPlan		streamline algorithm in MITK		Gibbs algorithm in MITK
	seed		seed		
	GTV <sub>+4mm</sub>	recurrence	GTV <sub>+4mm</sub>	recurrence	
1 (recurrence 1)	no	no	no	no	yes (strong, 16)
1 (recurrence 2)	no	no	no	no	yes (strong, 41)
2	no	no	no	no	yes (weak, 1)
3	no	yes (middle)	no	no	no
4	no	no	no	no	yes (weak, 7)
5	no	yes (strong)	no	no	yes (strong, 34)
6 (recurrence 1)	yes (strong)	yes (strong)	yes (weak)	yes (middle)	yes (strong, 95)
6 (recurrence 2)	no	yes (weak)	no	no	yes (middle, 13)
7 (recurrence 1)	no	no	no	no	yes (middle, 16)
7 (recurrence 2)	no	no	no	no	yes (strong, 48)

Observed connections between GTV extended by 2 mm / 4 mm and recurrence volume considering fibers generated by streamline algorithm in iPlan and MITK and by the Gibbs tracking algorithm in MITK with subjective rating of the strength of connection (weak, middle, strong). For the Gibbs tracking algorithm, the number of fibers passing GTV<sub>+2mm</sub> / GTV<sub>+4mm</sub> and recurrence is stated.

<https://doi.org/10.1371/journal.pone.0227146.t001>

## Conclusion

The study investigated the use of DTI based fiber tracking to predict the position of potential recurrences in GBM patients, which might be helpful for the definition of the PTV. The observed fibers were dependent on the used tracking algorithm and most of the recurrences could not be properly connected to the GTV in a prospective, i.e. predictive, manner. Based on the results of this study, it seems not recommendable to adapt the PTV definition for GBM patients including potential distance recurrences with fiber tracking based on the clinical DTI data acquisition techniques described in this study.

## Acknowledgments

The presented work was performed in partial fulfilment of the requirements for obtaining the degree Dr. rer. biol. hum. at the Friedrich-Alexander-Universität (FAU). BW thanks Angelika Mennecke from the Department of Neuroradiology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg for good cooperation.

## Author Contributions

**Conceptualization:** Barbara Witulla, Nicole Goerig, Florian Putz, Benjamin Frey, Rainer Fietkau, Christoph Bert, Frederik Bernd Laun.

**Data curation:** Nicole Goerig, Florian Putz, Tobias Engelhorn, Arnd Dörfler, Michael Uder.

**Formal analysis:** Barbara Witulla, Frederik Bernd Laun.

**Methodology:** Barbara Witulla, Tobias Engelhorn, Rainer Fietkau, Frederik Bernd Laun.

**Project administration:** Benjamin Frey, Rainer Fietkau.

**Resources:** Arnd Dörfler, Michael Uder, Rainer Fietkau.

**Software:** Barbara Witulla.

**Supervision:** Tobias Engelhorn, Arnd Dörfler, Michael Uder, Rainer Fietkau, Christoph Bert, Frederik Bernd Laun.

**Validation:** Barbara Witulla, Frederik Bernd Laun.

**Writing – original draft:** Barbara Witulla, Christoph Bert, Frederik Bernd Laun.

**Writing – review & editing:** Nicole Goerig, Florian Putz, Christoph Bert, Frederik Bernd Laun.

## References

1. Behin A, Hoang-Xuan K, Carpentier AF, Delattre J-Y. Primary brain tumours in adults. *Lancet*. 2003; 361(9354):323–31. [https://doi.org/10.1016/S0140-6736\(03\)12328-8](https://doi.org/10.1016/S0140-6736(03)12328-8) PMID: 12559880
2. Krebs in Deutschland 2013/2014. 11 ed. Berlin: Robert Koch-Institut und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.; 2017.
3. Notohamiprodjo M, Chandarana H, Mikheev A, Rusinek H, Grinstead J, Feiweier T, et al. Combined intravoxel incoherent motion and diffusion tensor imaging of renal diffusion and flow anisotropy. *Magnetic resonance in medicine*. 2015; 73(4):1526–32. <https://doi.org/10.1002/mrm.25245> PMID: 24752998.
4. Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. *J Clin Oncol*. 2017; 35(3):361–9. <https://doi.org/10.1200/JCO.2016.70.7562> PMID: 27893327.
5. Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). *J Clin Neurosci*. 2013; 20(5):670–5. <https://doi.org/10.1016/j.jocn.2012.05.040> PMID: 23352352.
6. Azizi AA, Paur S, Kaider A, Dieckmann K, Peyrl A, Chocholous M, et al. Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma? *Strahlenther Onkol*. 2018; 194(6):552–9. <https://doi.org/10.1007/s00066-018-1260-z> PMID: 29349602
7. Straube C, Elpula G, Gempt J, Gerhardt J, Bette S, Zimmer C, et al. Re-irradiation after gross total resection of recurrent glioblastoma. *Strahlenther Onkol*. 2017; 193(11):897–909. <https://doi.org/10.1007/s00066-017-1161-6> PMID: 28616821
8. Adeberg S, König L, Bostel T, Harrabi S, Welzel T, Debus J, et al. Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. *Int J Radiat Oncol Biol Phys*. 2014; 90(4):886–93. <https://doi.org/10.1016/j.ijrobp.2014.07.027> PMID: 25220720.
9. Giese A, Westphal M. Glioma invasion in the central nervous system. *Neurosurgery*. 1996; 39(2):235–50; discussion 50–2. <https://doi.org/10.1097/00006123-199608000-00001> PMID: 8832660.
10. Laun FB, Fritzsche KH, Kuder TA, Stieltjes B. [Introduction to the basic principles and techniques of diffusion-weighted imaging]. *Radiologe*. 2011; 51(3):170–9. <https://doi.org/10.1007/s00117-010-2057-y> PMID: 21424762.
11. Mori S, Kaufmann WE, Pearlson GD, Crain BJ, Stieltjes B, Solaiyappan M, et al. In vivo visualization of human neural pathways by magnetic resonance imaging. *Ann Neurol*. 2000; 47(3):412–4. [https://doi.org/10.1002/1531-8249\(200003\)47:3<412::AID-ANA28>3.0.CO;2-H](https://doi.org/10.1002/1531-8249(200003)47:3<412::AID-ANA28>3.0.CO;2-H) PMID: 10716271
12. Krishnan AP, Asher IM, Davis D, Okunieff P, O'Dell WG. Evidence that MR diffusion tensor imaging (tractography) predicts the natural history of regional progression in patients irradiated conformally for

- primary brain tumors. *Int J Radiat Oncol Biol Phys*. 2008; 71(5):1553–62. <https://doi.org/10.1016/j.ijrobp.2008.04.017> PMID: 18538491.
13. Brainlab. iPlan Fiber Tracking—clinical white paper.
  14. Reisert M, Mader I, Anastasopoulos C, Weigel M, Schnell S, Kiselev V. Global fiber reconstruction becomes practical. *Neuroimage*. 2011; 54(2):955–62. <https://doi.org/10.1016/j.neuroimage.2010.09.016> PMID: 20854913.
  15. Neher PF, Côté M-A, Houde J-C, Descoteaux M, Maier-Hein KH. Fiber tractography using machine learning. *Neuroimage*. 2017; 158:417–29. <https://doi.org/10.1016/j.neuroimage.2017.07.028> PMID: 28716716
  16. Weinstein D, Kindlmann G, Lundberg E, editors. Tensorlines: advection-diffusion based propagation through diffusion tensor fields. Visualization '99 Proceedings; 1999.
  17. Lazar M, Weinstein DM, Tsuruda JS, Hasan KM, Arfanakis K, Meyerand ME, et al. White matter tractography using diffusion tensor deflection. *Hum Brain Mapp*. 2003; 18(4):306–21. <https://doi.org/10.1002/hbm.10102> PMID: 12632468.
  18. Chamberland M, Whittingstall K, Fortin D, Mathieu D, Descoteaux M. Real-time multi-peak tractography for instantaneous connectivity display. *Front Neuroinform*. 2014; 8(59). <https://doi.org/10.3389/fninf.2014.00059> PMID: 24910610
  19. Tournier J-D, Calamante F, Connelly A. MRtrix: Diffusion tractography in crossing fiber regions. *Int J Imaging Syst Technol*. 2012; 22(1):53–66. <https://doi.org/10.1002/ima.22005>
  20. Mori S, van Zijl PCM. Fiber tracking: principles and strategies—a technical review. *NMR Biomed*. 2002; 15(7–8):468–80. <https://doi.org/10.1002/nbm.781> PMID: 12489096.
  21. Neher PF, Laun FB, Stieltjes B, Maier-Hein KH. Fiberfox: facilitating the creation of realistic white matter software phantoms. *Magn Reson Med*. 2014; 72(5):1460–70. <https://doi.org/10.1002/mrm.25045> PMID: 24323973.
  22. Bach M, Fritzsche KH, Stieltjes B, Laun FB. Investigation of resolution effects using a specialized diffusion tensor phantom. *Magn Reson Med*. 2014; 71(3):1108–16. <https://doi.org/10.1002/mrm.24774> PMID: 23657980.
  23. Takemura H, Caiafa CF, Wandell BA, Pestilli F. Ensemble Tractography. *PLoS Comput Biol*. 2016; 12(2):e1004692. <https://doi.org/10.1371/journal.pcbi.1004692> PMID: 26845558
  24. Berberat J, McNamara J, Remonda L, Bodis S, Rogers S. Diffusion tensor imaging for target volume definition in glioblastoma multiforme. *Strahlenther Onkol*. 2014; 190(10):939–43. <https://doi.org/10.1007/s00066-014-0676-3> PMID: 24823897.
  25. Jensen MB, Guldborg TL, Harboll A, Lukacova S, Kallehauge JF. Diffusion tensor magnetic resonance imaging driven growth modeling for radiotherapy target definition in glioblastoma. *Acta Oncol*. 2017; 56(11):1639–43. <https://doi.org/10.1080/0284186X.2017.1374559> PMID: 28893125.
  26. Unkelbach J, Menze BH, Konukoglu E, Dittmann F, Le M, Ayache N, et al. Radiotherapy planning for glioblastoma based on a tumor growth model: improving target volume delineation. *Phys Med Biol*. 2014; 59(3):747–70. <https://doi.org/10.1088/0031-9155/59/3/747> PMID: 24440875.
  27. Angeli S, Emblem KE, Due-Tonnessen P, Stylianopoulos T. Towards patient-specific modeling of brain tumor growth and formation of secondary nodes guided by DTI-MRI. *Neuroimage Clin*. 2018; 20:664–73. <https://doi.org/10.1016/j.nicl.2018.08.032> PMID: 30211003.
  28. Bondiau PY, Konukoglu E, Clatz O, Delingette H, Frenay M, Paquis P. Biocomputing: numerical simulation of glioblastoma growth and comparison with conventional irradiation margins. *Phys Med*. 2011; 27(2):103–8. <https://doi.org/10.1016/j.ejmp.2010.05.002> PMID: 21071253.
  29. Hathout L, Patel V, Wen P. A 3-dimensional DTI MRI-based model of GBM growth and response to radiation therapy. *Int J Oncol*. 2016; 49(3):1081–7. <https://doi.org/10.3892/ijo.2016.3595> PMID: 27572745.
  30. Jbabdi S, Mandonnet E, Duffau H, Capelle L, Swanson KR, Pelegriani-Issac M, et al. Simulation of anisotropic growth of low-grade gliomas using diffusion tensor imaging. *Magn Reson Med*. 2005; 54(3):616–24. <https://doi.org/10.1002/mrm.20625> PMID: 16088879.
  31. Freitag MT, Maier-Hein KH, Binczyk F, Laun FB, Weber C, Bonekamp D, et al. Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures. *PLoS One*. 2016; 11(10):e0164679. <https://doi.org/10.1371/journal.pone.0164679> PMID: 27741525.
  32. Wang S, Kim SJ, Poptani H, Woo JH, Mohan S, Jin R, et al. Diagnostic utility of diffusion tensor imaging in differentiating glioblastomas from brain metastases. *AJNR Am J Neuroradiol*. 2014; 35(5):928–34. <https://doi.org/10.3174/ajnr.A3871> PMID: 24503556.
  33. Abhinav K, Yeh FC, Mansouri A, Zadeh G, Fernandez-Miranda JC. High-definition fiber tractography for the evaluation of perilesional white matter tracts in high-grade glioma surgery. *Neuro Oncol*. 2015; 17(9):1199–209. <https://doi.org/10.1093/neuonc/nov113> PMID: 26117712.

34. Stieltjes B, Schluter M, Didinger B, Weber MA, Hahn HK, Parzer P, et al. Diffusion tensor imaging in primary brain tumors: reproducible quantitative analysis of corpus callosum infiltration and contralateral involvement using a probabilistic mixture model. *Neuroimage*. 2006; 31(2):531–42. <https://doi.org/10.1016/j.neuroimage.2005.12.052> PMID: 16478665.
35. Hart MG, Price SJ, Suckling J. Connectome analysis for pre-operative brain mapping in neurosurgery. *Brit J Neurosurg*. 2016; 30(5):506–17. <https://doi.org/10.1080/02688697.2016.1208809> PMID: 27447756
36. Alghamdi M, Hasan Y, Ruschin M, Atenafu EG, Myrehaug S, Tseng C-L, et al. Stereotactic radiosurgery for resected brain metastasis: Cavity dynamics and factors affecting its evolution. *Journal of Radiosurgery and SBRT*. 2018; 5(3):191–200. PMID: 29988304
37. Liu M, Gross DW, Wheatley BM, Concha L, Beaulieu C. The acute phase of Wallerian degeneration: Longitudinal diffusion tensor imaging of the fornix following temporal lobe surgery. *Neuroimage*. 2013; 74:128–39. <https://doi.org/10.1016/j.neuroimage.2013.01.069> PMID: 23396161
38. Beaulieu C, Does MD, Snyder RE, Allen PS. Changes in water diffusion due to Wallerian degeneration in peripheral nerve. *Magn Reson Med*. 1996; 36(4):627–31. <https://doi.org/10.1002/mrm.1910360419> PMID: 8892217
39. Cazzaniga LF, Marinoni MA, Bossi A, Bianchi E, Cagna E, Cosentino D, et al. Interphysician variability in defining the planning target volume in the irradiation of prostate and seminal vesicles. *Radiother Oncol*. 1998; 47(3):293–96. [https://doi.org/10.1016/s0167-8140\(98\)00028-0](https://doi.org/10.1016/s0167-8140(98)00028-0) PMID: 9681893
40. Kingsley PB. Introduction to diffusion tensor imaging mathematics: Part III. Tensor calculation, noise, simulations, and optimization. *Concept Magn Reson A*. 2006; 28a(2):155–79. <https://doi.org/10.1002/cmr.a.20050>
41. Jeurissen B, Leemans A, Jones DK, Tournier JD, Sijbers J. Probabilistic Fiber Tracking Using the Residual Bootstrap with Constrained Spherical Deconvolution. *Hum Brain Mapp*. 2011; 32(3):461–79. <https://doi.org/10.1002/hbm.21032> PMID: 21319270
42. Reddy CP, Rathi Y. Joint Multi-Fiber NODDI Parameter Estimation and Tractography Using the Unscented Information Filter. *Front Neurosci-Switz*. 2016; 10. <https://doi.org/10.3389/fnins.2016.00166> PMID: 27147956
43. Jayachandra MR, Rehbein N, Herweh C, Heiland S. Fiber Tracking of Human Brain Using Fourth-Order Tensor and High Angular Resolution Diffusion Imaging. *Magnetic resonance in medicine*. 2008; 60(5):1207–17. <https://doi.org/10.1002/mrm.21775> PMID: 18958858
44. Descoteaux M, Deriche R, Knosche TR, Anwander A. Deterministic and Probabilistic Tractography Based on Complex Fibre Orientation Distributions. *IEEE T Med Imaging*. 2009; 28(2):269–86. <https://doi.org/10.1109/Tmi.2008.2004424> PMID: 19188114
45. Polders DL, Leemans A, Hendrikse J, Donahue MJ, Luijten PR, Hoogduin JM. Signal to Noise Ratio and Uncertainty in Diffusion Tensor Imaging at 1.5, 3.0, and 7.0 Tesla. *Journal of Magnetic Resonance Imaging*. 2011; 33(6):1456–63. <https://doi.org/10.1002/jmri.22554> PMID: 21591016